<a href="https://www.fiercebiotech.com/biotech/drug-development-ma-big-pharmas-showcase-measurable-impact-ai" hreflang="en">From drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’</a>
Big Pharma companies are increasingly demonstrating the practical applications of artificial intelligence (AI) in drug development, with AstraZeneca showcasing its generative AI framework that has significantly reduced the time for identifying potential new medicines. Other firms like GSK, Bristol Myers Squibb, and Merck & Co. are also leveraging AI to enhance research and development processes, streamline clinical operations, and improve productivity across their organizations.
AstraZeneca's development of its open-source generative AI framework, Reinvent, which has significantly reduced drug development timelines by halving the time needed to identify molecular structures, is a compelling example of AI’s tangible impact on the pharmaceutical industry's R&D processes. This advancement, along with its QCS platform for patient identification in clinical trials, illustrates the actionable potential of AI in enhancing drug discovery and precision medicine, offering a strategic insight for those considering investments or partnerships in AI-driven biotech initiatives.